ReviewAnnals of neurology2026
Understanding Neurodegenerative Diseases From the -Omics Perspective: Lessons Learnt.
Review in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07516119 (Assessing Tools That Predict and Stage Mild Cognitive Impairment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Tools That Predict and Stage Mild Cognitive Impairment
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the population ages, certain neurodegenerative diseases (NDs) are becoming a major health issue. For this reason, this review will focus on the most common ND with onset after 65 years old; Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia. NDs are the results of multifactorial processes causing pleiotropic changes in molecular and protein networks linking a host of biological processes that lead to protein dysregulation and aggregation that ultimately leads to neurodegeneration. Genetic, transcriptomic, and proteomic studies have been instrumental to identify novel genes and proteins implicated on diseases that point to novel disease mechanism, as well as the identification of disease biomarkers. Here, we provide a review of the genomic, transcriptomic, and proteomic studies on ND so far, as well as future opportunities and challenges. ANN NEUROL 2026;99:566-587.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.